IDEA4RC FHIR Implementation Guide
1.0.0 - release 150

IDEA4RC FHIR Implementation Guide - Downloaded Version 1.0.0 See the Directory of published versions

Table of Contents

.. 0 Table of Contents
... 1 IDEA4RC FHIR IG - Home Page
... 2 IDEA4RC Model Overview
... 3 IDEA4RC Detailed ERD Model
... 4 IDEA4RC Logical Models
... 5 Useful Downloads
... 6 Condition-secondaryCancer-eu-i4rc Relationships
... 7 Encounter-eu-i4rc Relationships
... 8 Condition-primaryCancer-eu-i4rc Relationships
... 9 sarcoma-cancer-stage-group Relationships
... 10 hn-cancer-stage-group Relationships
... 11 episodeOfCare-eu-i4rc Relationships
... 12 MedicationAdministration-eu-i4rc Relationships
... 13 Subject Relationships
... 14 PatientFollowUp Relationships
... 15 EpisodeEvent Relationships
... 16 HospitalPatientRecords Relationships
... 17 CancerEpisode Relationships
... 18 AdverseEvent Relationships
... 19 GeneticTestExpression Relationships
... 20 Surgery Relationships
... 21 Radiotherapy Relationships
... 22 Adverse Event Model to this guide Map
... 23 Cancer Episode Model to this guide Map
... 24 Episode Event Model to this guide Map
... 25 Patient (Subject) Model to this guide Map
... 26 Diagnosis to this guide Map
... 27 Surgery Model to this guide Map
... 28 Radiotherapy Model to this guide Map
... 29 Patient Follow up Model to this guide Map
... 30 Genetic Test Expression Model to this guide Map
... 31 Hospital Patient Records Model to this guide Map
... 32 Isolated Limb Perfusion Model to this guide Map
... 33 Regional Deep Hyperthemia Model to this guide Map
... 34 Overall Treatment Response Model to this guide Map
... 35 Systemic Treatment Model to this guide Map
... 36 Drugs For Treatments Model to this guide Map
... 37 Clinical Stage Model to this guide Map
... 38 Pathological Stage Model to this guide Map
... 39 Disease Extent Model to this guide Map
... 40 Artifacts Summary
.... 40.1 Adverse Event
.... 40.2 Cancer Episode
.... 40.3 Clinical Stage
.... 40.4 Diagnosis
.... 40.5 Disease Extent
.... 40.6 Drugs For Treatments
.... 40.7 Episode Event
.... 40.8 Genetic Test Expression
.... 40.9 Hospital Patient Records
.... 40.10 IsolatedLimbPerfusion
.... 40.11 OverallTreatmentResponse
.... 40.12 Pathological Stage
.... 40.13 Patient
.... 40.14 Patient Follow-Up
.... 40.15 Radiotherapy
.... 40.16 RegionalDeepHyperthemia
.... 40.17 Surgery
.... 40.18 Systemic Treatment
.... 40.19 Observation: Alcohol use
.... 40.20 Observation: Cancer Treatment
.... 40.21 Observation: Charlson Comorbidity Index
.... 40.22 Observation: Comorbidities
.... 40.23 Observation: ECOG Performance Status
.... 40.24 Observation: Karnofsky Performance Status
.... 40.25 Observation: Occurrence of the other cancer
.... 40.26 Observation: Tobacco use
.... 40.27 Patient: IDEA4RC
.... 40.28 Condition: Primary Cancer
.... 40.29 Observation: Diagnosis details
.... 40.30 Observation: Head Neck Cancer Stage Group
.... 40.31 Observation: Localized Category (Stage, Sarcoma)
.... 40.32 Observation: LocoRegional Category (Stage)
.... 40.33 Observation: Number of tumor nodules
.... 40.34 Observation: Radiological Extra-nodal extension (rENE)
.... 40.35 Observation: Sarcoma Cancer and Disease Extent Stage Group
.... 40.36 Observation: TNM Distant Metastases Category
.... 40.37 Observation: TNM Primary Tumor Category
.... 40.38 Observation: TNM Regional Nodes Category
.... 40.39 Encounter: IDEA4RC
.... 40.40 Observation: date of the last contact
.... 40.41 Observation: Status at the Last Follow Up
.... 40.42 Procedure: Surgery
.... 40.43 Procedure: Radiotherapy
.... 40.44 MedicationAdministration: Chemotherapy
.... 40.45 EpisodeOfCare: IDEA4RC
.... 40.46 AdverseEvent: IDEA4RC
.... 40.47 Bundle: IDEA4RC
.... 40.48 Condition: Metastatic Cancer
.... 40.49 Observation: Genetic Test Expression
.... 40.50 Observation: Overall Treatment
.... 40.51 Observation: test results
.... 40.52 Observation: Tumor Rupture
.... 40.53 Observation: Yes / No assertions
.... 40.54 Procedure: Immaging for Clinical Stage
.... 40.55 Procedure: Other Treatment
.... 40.56 Substance : Other Treatment
.... 40.57 Adaptive
.... 40.58 Body Location Qualifier
.... 40.59 Chemotherapy Timing
.... 40.60 Condition related to resource
.... 40.61 Histology Morphology Behavior
.... 40.62 Laterality Qualifier
.... 40.63 Medication Outcome
.... 40.64 MedicationAdministration Category
.... 40.65 Performed Timing
.... 40.66 Previous Status
.... 40.67 Procedure Category
.... 40.68 Race Extension
.... 40.69 Radiotherapy Dose Delivered To Volume Extension
.... 40.70 Radiotherapy Energy or Isotope
.... 40.71 Radiotherapy Modality And Technique Extension
.... 40.72 Radiotherapy Modality Extension
.... 40.73 Radiotherapy Number of Sessions Extension
.... 40.74 Radiotherapy Setting
.... 40.75 Radiotherapy Technique Extension
.... 40.76 Relapse Type
.... 40.77 Same custodian flag
.... 40.78 Same Hospital
.... 40.79 Total High Dose Delivered
.... 40.80 Adverse Event Type
.... 40.81 Affected Organs (surgery)
.... 40.82 Alcohol Usage Status: Athena
.... 40.83 Alcohol Usage Status: SNOMED CT
.... 40.84 Antineoplastic and immunostimulating agents
.... 40.85 Beam Quality
.... 40.86 Body site qualifier
.... 40.87 Calculated|Estimated
.... 40.88 Cancer Diagnosis: Athena
.... 40.89 Cancer histology behaviour: Athena
.... 40.90 Cancer histology subgroup: Athena
.... 40.91 Cancer histology: Athena
.... 40.92 Cancer site: Athena
.... 40.93 Cancer Stage Grading: Athena
.... 40.94 Cancer Stage Group Value Clinical: Athena
.... 40.95 Cancer Stage Group Value Pathological: Athena
.... 40.96 Cancer Stage Group Value: Athena
.... 40.97 Cancer Stage Group: Athena
.... 40.98 Chemotherapy cumulative dose units
.... 40.99 Chemotherapy Info
.... 40.100 Clinical TNM Primary Tumor Category Value Set
.... 40.101 Coded test results: Athena.
.... 40.102 Comorbidities: Athena
.... 40.103 Comorbidities: SNOMED
.... 40.104 Country: athena
.... 40.105 Current Smoking Status: Athena
.... 40.106 Disease Status: Athena
.... 40.107 Drugs for Systemic Treatment
.... 40.108 Drugs for Treatments
.... 40.109 ECOG Performance Status
.... 40.110 Event Type
.... 40.111 Extranodal Extension
.... 40.112 Gender: Athena
.... 40.113 Genetic test expression
.... 40.114 Genetic Tests performed (Yes/no/Unk)
.... 40.115 Genito urinary subsite: Athena
.... 40.116 Hypopharynx subsite: Athena
.... 40.117 Hypopharynx subsite: Snomed CT
.... 40.118 Immaging Body sites
.... 40.119 Immaging Clinical Stage
.... 40.120 Immaging Clinical Stage Metastasis
.... 40.121 Immaging Clinical Stage Neck
.... 40.122 Immaging Clinical Stage Primary Site
.... 40.123 Intra abdominal subsite: Athena
.... 40.124 Intra thoracic subsite : Athena
.... 40.125 Larynx subsite: Athena
.... 40.126 Larynx subsite: Snomed CT
.... 40.127 Lip subsite: Athena
.... 40.128 Lip subsite: Snomed CT
.... 40.129 Margins After Surgery
.... 40.130 Metastatis: Athena
.... 40.131 Mitotic Index: Athena.
.... 40.132 Nasal cavity and paranasal sinuses subsite: Athena
.... 40.133 Nasal cavity and paranasal sinuses subsite: Snomed CT
.... 40.134 Nasopharynx subsite: Athena
.... 40.135 Nasopharynx subsite: Snomed CT
.... 40.136 Not Performed|Unknown
.... 40.137 Observation Codes for Distant Metastases Category
.... 40.138 Observation Codes for Primary Tumor Category
.... 40.139 Observation Codes for Regional Node Category
.... 40.140 Occurrence of other cancer
.... 40.141 Oral cavity subsite: Athena
.... 40.142 Oral cavity subsite: Snomed CT
.... 40.143 Oropharynx subsite: Athena
.... 40.144 Oropharynx subsite: Snomed CT
.... 40.145 Other Treatment Procedure Type
.... 40.146 Pathological M
.... 40.147 Pathological N
.... 40.148 Pathological T
.... 40.149 Pathological TNM Primary Tumor Category Value Set
.... 40.150 Positive-Negative-No Test: Athena
.... 40.151 Positive-Negative-No Test: Athena
.... 40.152 Race
.... 40.153 Radiotherapy Device Type
.... 40.154 Radiotherapy Site Laterality Qualifier
.... 40.155 Radiotherapy Sites
.... 40.156 Re-irradiation reason
.... 40.157 Reason to End Treatment
.... 40.158 Regimen
.... 40.159 Sarcoma Staging: localized disease
.... 40.160 Setting Radiotherapy
.... 40.161 Simple measures
.... 40.162 Site of metastasis
.... 40.163 Site rare (IDEA4RC)
.... 40.164 Site: Athena
.... 40.165 Smoking Status: LOINC
.... 40.166 Staging: loco-regional category
.... 40.167 Status at the Last Follow Up
.... 40.168 Subsites: Athena
.... 40.169 Subsites: SNOMED CT
.... 40.170 Surgery Complication
.... 40.171 Surgery Intention
.... 40.172 Surgery Location Qualifier
.... 40.173 Surgery Outcome
.... 40.174 Surgery Site Laterality Qualifier
.... 40.175 Surgery Sites
.... 40.176 Surgical Complications
.... 40.177 Surgical Procedure Category
.... 40.178 Surgical Procedure Type
.... 40.179 TNM Distant Metastases Category Value Set (Clinical)
.... 40.180 TNM Distant Metastases Category Value Set (Pathological)
.... 40.181 TNM Primary Tumor Category Value Set
.... 40.182 TNM Regional Nodes Category Value Set (Clinical)
.... 40.183 TNM Regional Nodes Category Value Set (Pathological)
.... 40.184 Tobacco Product
.... 40.185 Treatment completed as planned
.... 40.186 Treatment Response
.... 40.187 Treatment Setting
.... 40.188 Treatment Technique
.... 40.189 Trunk wall subsite: Athena
.... 40.190 Type of Biopsy
.... 40.191 Type of Diagnosis
.... 40.192 Type of surgical approach
.... 40.193 Type of Systemic Treatment
.... 40.194 Type of Treatment
.... 40.195 Types of Yes/No observations
.... 40.196 Upper and Lower limbs subsite: Athena
.... 40.197 Yes-No-Unk: Athena
.... 40.198 IDEA4RC Body Topography Code System
.... 40.199 IDEA4RC Cancer Diagnosis Code System
.... 40.200 IDEA4RC Code System
.... 40.201 IDEA4RC Vocabulary Code System
.... 40.202 Actor: Head and Neck
.... 40.203 Actor: Sarcoma
.... 40.204 Condition: Grade 2 tumor with several body sites and evidences
.... 40.205 Condition: Metastasis bone and pleura
.... 40.206 Condition: NOT CLEAR WHAT IT REPRESENTS..TO BE DISCUSSED
.... 40.207 Condition: Secondary cancer with multiple metastatic body sites
.... 40.208 Condition: Stable Disease
.... 40.209 Encounter: planned inpatient encounter
.... 40.210 EpisodeOfCare
.... 40.211 MedicationAdministration: Neoadjuvant chemotherapy
.... 40.212 Observation: Alcohol use
.... 40.213 Observation: BMI
.... 40.214 Observation: C reactive protein Positive
.... 40.215 Observation: Charlson Comorbidity Index
.... 40.216 Observation: comorbidity
.... 40.217 Observation: date of the last contact
.... 40.218 Observation: Diagnosis
.... 40.219 Observation: Dimension of Tumor
.... 40.220 Observation: Distant metastases clinical M1
.... 40.221 Observation: Distant metastases pathology M1
.... 40.222 Observation: ECOG Performance Status score
.... 40.223 Observation: Epstein Barr virus DNA Negative
.... 40.224 Observation: gene Mutation Analysis Performed yes
.... 40.225 Observation: Human papilloma virus Negative
.... 40.226 Observation: immunohiostochemestry analysis performed
.... 40.227 Observation: Karnofsky Performance Status score
.... 40.228 Observation: Number of mitoses per HPF
.... 40.229 Observation: Occurrence of other Cancer: Hamartoma
.... 40.230 Observation: Primary tumor clinical T0
.... 40.231 Observation: Primary tumor pathological T0
.... 40.232 Observation: Radiological Extra-nodal extension
.... 40.233 Observation: Regional lymph nodes Clinical N1
.... 40.234 Observation: Regional lymph nodes pathology N3b
.... 40.235 Observation: Surgery treatment occurred
.... 40.236 Observation: TNM clinical stage grouping
.... 40.237 Observation: TNM pathology stage grouping
.... 40.238 Observation: Tobacco use panel
.... 40.239 Patient: race extension
.... 40.240 Procedure: Isolated limb perfusion
.... 40.241 Procedure: Radiotherapy